DE69739760D1 - Verwendung eines Galanin-agonisten in der Herstellung eines Medikaments zur Verbesserung des Gedächtnisses und anderer cognitiver Funktionen - Google Patents

Verwendung eines Galanin-agonisten in der Herstellung eines Medikaments zur Verbesserung des Gedächtnisses und anderer cognitiver Funktionen

Info

Publication number: DE69739760D1
Authority: DE; Germany
Prior art keywords: galanin; improving memory; medicament; manufacture; treatment
Prior art date: 1996-07-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69739760T

Other languages

English (en)

Inventor

David Wynick

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Neurotargets Ltd

Original Assignee

Neurotargets Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-24

Filing date

1997-07-24

Publication date

2010-03-25

1996-07-24 Priority claimed from GBGB9615551.0A external-priority patent/GB9615551D0/en

1996-11-15 Priority claimed from GBGB9623869.6A external-priority patent/GB9623869D0/en

1997-07-24 Application filed by Neurotargets Ltd filed Critical Neurotargets Ltd

2010-03-25 Application granted granted Critical

2010-03-25 Publication of DE69739760D1 publication Critical patent/DE69739760D1/de

2017-07-25 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

101800002068 Galanin Proteins 0.000 title abstract 6
102000019432 Galanin Human genes 0.000 title abstract 5
SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 title abstract 5
239000000556 agonist Substances 0.000 title abstract 2
230000003920 cognitive function Effects 0.000 title 1
239000003814 drug Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
230000036407 pain Effects 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010002091 Anaesthesia Diseases 0.000 abstract 1
208000028389 Nerve injury Diseases 0.000 abstract 1
206010036832 Prolactinoma Diseases 0.000 abstract 1
230000037005 anaesthesia Effects 0.000 abstract 1
238000001949 anaesthesia Methods 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
230000019771 cognition Effects 0.000 abstract 1
238000011813 knockout mouse model Methods 0.000 abstract 1
210000005036 nerve Anatomy 0.000 abstract 1
230000008764 nerve damage Effects 0.000 abstract 1
208000005877 painful neuropathy Diseases 0.000 abstract 1
208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 abstract 1
230000008929 regeneration Effects 0.000 abstract 1
238000011069 regeneration method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Environmental Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Biodiversity & Conservation Biology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Animal Husbandry (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Biochemistry (AREA)

DE69739760T 1996-07-24 1997-07-24 Verwendung eines Galanin-agonisten in der Herstellung eines Medikaments zur Verbesserung des Gedächtnisses und anderer cognitiver Funktionen Expired - Lifetime DE69739760D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9615551.0A GB9615551D0 (en)	1996-07-24	1996-07-24	Galanin
GBGB9623869.6A GB9623869D0 (en)	1996-11-15	1996-11-15	Galanin

Publications (1)

Publication Number	Publication Date
DE69739760D1 true DE69739760D1 (de)	2010-03-25

Family

ID=26309752

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE69739760T Expired - Lifetime DE69739760D1 (de)	1996-07-24	1997-07-24	Verwendung eines Galanin-agonisten in der Herstellung eines Medikaments zur Verbesserung des Gedächtnisses und anderer cognitiver Funktionen
DE69721005T Expired - Lifetime DE69721005T2 (de)	1996-07-24	1997-07-24	Gebrauch von galanin um nervenschäden zu reparieren

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE69721005T Expired - Lifetime DE69721005T2 (de)	1996-07-24	1997-07-24	Gebrauch von galanin um nervenschäden zu reparieren

Country Status (11)

Country	Link
US (1)	US20030009777A1 (de)
EP (2)	EP1342410B1 (de)
JP (1)	JP2000516212A (de)
AT (2)	ATE237346T1 (de)
AU (1)	AU3630297A (de)
DE (2)	DE69739760D1 (de)
DK (2)	DK1342410T3 (de)
ES (2)	ES2340984T3 (de)
GB (1)	GB2331301C (de)
PT (2)	PT918455E (de)
WO (1)	WO1998003059A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2000504107A (ja)	1996-01-24	2000-04-04	シナプティック・ファーマスーティカル・コーポレーション	ガラニンｇａｌｒ２受容体をコードするｄｎａおよびその使用
US6329197B2 (en)	1996-10-09	2001-12-11	Synaptic Pharmaceutical Corporation	DNA encoding galanin GALR3 receptors and uses thereof
US20030092042A1 (en) *	2001-08-27	2003-05-15	David Mu	Amplified oncogenes and their involvement in cancer
WO2003070950A1 (fr) *	2002-02-22	2003-08-28	Takeda Chemical Industries, Ltd.	Nouvel adn et utilisation correspondante
GB0403509D0 (en) *	2004-02-17	2004-03-24	Neuro Targets Ltd	Galanin receptors and brain injury
CA2580690A1 (en)	2004-10-21	2006-05-04	Transtech Pharma, Inc.	Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
GB0523550D0 (en)	2005-11-18	2005-12-28	Hunter Fleming Ltd	Therapeutic uses of steroidal compounds
AU2008207287A1 (en) *	2007-01-19	2008-07-24	Howard Florey Institute Of Experimental Physiology And Medicine	Use of galanin in a method of treating neurodegenerative diseases or conditions
AU2008306141A1 (en) *	2007-09-11	2009-04-09	Mondobiotech Laboratories Ag	Thyrotropin releasing hormone for therapeutic applications
US20100204129A1 (en) *	2008-09-09	2010-08-12	Dorian Bevec	Use of a peptide as a therapeutic agent
ES2883838A1 (es) *	2020-06-04	2021-12-09	Univ Malaga	Prevencion y/o tratamiento del deterioro cognitivo asociado a sindromes de demencia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992012997A1 (en) *	1991-01-16	1992-08-06	The General Hospital Corporation	Human galanin
WO1992015015A1 (en) *	1991-02-25	1992-09-03	Zymogenetic, Inc.	Methods for detecting galanin antagonists
DE69225706T2 (de) *	1991-03-06	1998-11-26	Garvan Institute Of Medical Research, Darlinghurst, Neu Sued Wales/New South Wales	Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen
SE9101472D0 (sv) *	1991-05-15	1991-05-15	Trion Forskning & Utveckling	Galanin antagonist
JPH06172387A (ja) *	1992-12-11	1994-06-21	Aibaitsu Kk	合成ペプチド誘導体
US6225282B1 (en) *	1996-01-05	2001-05-01	Genentech, Inc.	Treatment of hearing impairments
JP2000504107A (ja) *	1996-01-24	2000-04-04	シナプティック・ファーマスーティカル・コーポレーション	ガラニンｇａｌｒ２受容体をコードするｄｎａおよびその使用

1997
- 1997-07-24 ES ES02028584T patent/ES2340984T3/es not_active Expired - Lifetime
- 1997-07-24 PT PT97932939T patent/PT918455E/pt unknown
- 1997-07-24 EP EP02028584A patent/EP1342410B1/de not_active Expired - Lifetime
- 1997-07-24 AT AT97932939T patent/ATE237346T1/de not_active IP Right Cessation
- 1997-07-24 ES ES97932939T patent/ES2196349T3/es not_active Expired - Lifetime
- 1997-07-24 DE DE69739760T patent/DE69739760D1/de not_active Expired - Lifetime
- 1997-07-24 GB GB9901264A patent/GB2331301C/en not_active Expired - Fee Related
- 1997-07-24 PT PT02028584T patent/PT1342410E/pt unknown
- 1997-07-24 DK DK02028584.7T patent/DK1342410T3/da active
- 1997-07-24 AT AT02028584T patent/ATE457125T1/de not_active IP Right Cessation
- 1997-07-24 EP EP97932939A patent/EP0918455B1/de not_active Expired - Lifetime
- 1997-07-24 AU AU36302/97A patent/AU3630297A/en not_active Abandoned
- 1997-07-24 DK DK97932939T patent/DK0918455T3/da active
- 1997-07-24 JP JP10506711A patent/JP2000516212A/ja not_active Ceased
- 1997-07-24 US US09/230,463 patent/US20030009777A1/en not_active Abandoned
- 1997-07-24 WO PCT/GB1997/001991 patent/WO1998003059A1/en not_active Ceased
- 1997-07-24 DE DE69721005T patent/DE69721005T2/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
GB2331301A (en)	1999-05-19
EP0918455B1 (de)	2003-04-16
PT1342410E (pt)	2010-05-11
AU3630297A (en)	1998-02-10
US20030009777A1 (en)	2003-01-09
ES2196349T3 (es)	2003-12-16
WO1998003059A1 (en)	1998-01-29
EP1342410A3 (de)	2003-12-10
GB2331301B (en)	2001-02-14
DK1342410T3 (da)	2010-05-31
DK0918455T3 (da)	2003-08-04
ES2340984T3 (es)	2010-06-14
EP1342410A2 (de)	2003-09-10
JP2000516212A (ja)	2000-12-05
ATE237346T1 (de)	2003-05-15
ATE457125T1 (de)	2010-02-15
PT918455E (pt)	2003-09-30
GB2331301C (en)	2005-05-22
GB9901264D0 (en)	1999-03-10
DE69721005D1 (de)	2003-05-22
EP0918455A1 (de)	1999-06-02
EP1342410B1 (de)	2010-02-10
DE69721005T2 (de)	2004-06-09

Publication	Publication Date	Title
ATE293989T1 (de)	2005-05-15	Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
ATE328609T1 (de)	2006-06-15	Zusammensetzungen zur behandlung von parkinson's krankheit, welche antagonisten der cb1-rezeptoren und aktivierungssubstanzen der dopamin- neurotransmission im gehirn enthalten
DE60031396D1 (de)	2006-11-30	Zubereitung zur behandlung von einer neurologischen erkrankung
BRPI0414277A (pt)	2006-11-07	métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
ATE396973T1 (de)	2008-06-15	Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
DE69835103D1 (de)	2006-08-10	Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
ATE399553T1 (de)	2008-07-15	Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE60120372D1 (de)	2006-07-20	Verwendung von insulin zur behandlung von knorpelkrankheiten
AP2001002129A0 (en)	2001-06-30	5HT1 receptor agonists and metoclopramide for the treatment of migrane.
ATE490786T1 (de)	2010-12-15	Behandlung von verletzungen des zentralen nervensystems
DE69739760D1 (de)	2010-03-25	Verwendung eines Galanin-agonisten in der Herstellung eines Medikaments zur Verbesserung des Gedächtnisses und anderer cognitiver Funktionen
ATE309782T1 (de)	2005-12-15	Zusammensetzung zur narbenbehandlung enthaltend eine silikonmischung
YU13301A (sh)	2005-06-10	Muskarinski agonisti i antagonisti
ATE369348T1 (de)	2007-08-15	Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
AU5548801A (en)	2001-11-07	Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
DE69733169D1 (de)	2005-06-09	Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
BR0015781A (pt)	2002-12-31	Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
ATE407925T1 (de)	2008-09-15	1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
EA200200656A1 (ru)	2002-12-26	НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
IL189190A0 (en)	2008-06-05	Use of fluorinated triazoles for treating pain and affective or attention disorders
DE69941134D1 (de)	2009-08-27	Verwendung von R (+)- g(a)-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol zur Behandlung von Schlafstörungen
DE602004015321D1 (de)	2008-09-04	1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen

Legal Events

Date	Code	Title	Description
2011-03-03	8364	No opposition during term of opposition